Sirna Therapeutics to Report Fourth Quarter and Full Year 2005 Financial Results on March 1, 200624 February 2006
Sirna Therapeutics, Inc. (Nasdaq: RNAI), a leading RNAi therapeutics company, announced today that it will release fourth quarter and full year financial results for the period ended December 31, 2005 after the close of U.S. financial markets on Wednesday, March 1, 2006.
Howard W. Robin, Sirna President and CEO, and the Sirna senior management team will discuss progress to date in their clinical and preclinical programs and provide an overview of financial results during a conference call on Wednesday, March 1st at 4:30 p.m. EST (2:30 p.m. MST; 1:30 p.m. PST).
A live audio webcast of the call will be available at the Company's corporate web site at http://www.sirna.com. Participants are urged to log on to the web site 15 minutes prior to the scheduled start time to download and install any necessary audio software. To access the live telephonic broadcast, domestic callers should dial (877) 502-9274; international callers may dial (913) 981-5584.
An audio webcast replay will be available on Sirna's web site, http://www.sirna.com, for 60 days. Additionally, a telephonic replay of the call will be maintained through midnight, Wednesday, March 15, 2006. To access the replay, please dial (888) 203-1112 from the U.S. or (719) 457-0820 when calling internationally, using confirmation code 5659654.
About Sirna Therapeutics
Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington's disease, diabetes and oncology. Sirna Therapeutics has presented interim Phase 1 clinical trial data for its most advanced compound, Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. Sirna-027, which has been partnered with Allergan, Inc., continues to demonstrate that it is safe and well tolerated with 100% of patients showing visual acuity stabilization after eight weeks from a single injection. In addition, Sirna recently announced that it has selected Sirna-AV34, a systemically delivered, optimized siRNA compound, as its candidate for advancement to human clinical testing against Hepatitis C virus. Sirna has a leading intellectual property portfolio in RNAi with 49 issued patents and over 240 pending applications worldwide. More information on Sirna Therapeutics is available on the Company's web site at http://www.sirna.com
Safe Harbor Statement
Statements in this press release which are not strictly historical are "forward-looking" statements which should be considered as subject to many risks and uncertainties. For example, most drug candidates do not become approved drugs. Moreover, Sirna's ability to develop products and operate as a going concern requires significant cash to fund its operating programs. Additional risks and uncertainties include Sirna's early stage of development and short operating history, Sirna's history and expectation of losses and need to raise capital, Sirna's need to obtain clinical validation and regulatory approval for products, Sirna's need to obtain and protect intellectual property, risk of third-party patent infringement claims, Sirna's need to attract and retain qualified personnel, Sirna's need to engage collaborators, availability of materials for product manufacturing, the highly competitive nature of the pharmaceutical market, the limited trading volume and history of volatility of Sirna's common stock, Sirna's concentration of stock ownership, and risks from relocating Sirna headquarters. These and additional risk factors are identified in Sirna's Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings. Sirna undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Contacts:
Rebecca Galler Robison
Sirna Therapeutics, Inc.
Senior Director, Corporate Strategy
(303) 449-6500
Investors
Francesca DeMartino
The Ruth Group
(646) 536-7024; fdemartino@theruthgroup.com
Source: prnewswire
All trademarks and copyrighted information contained herein are the property of their respective owners.
Related Computer Hardware Articles
|
